Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials

Sachin Ananth; Fekri Abroug; Alvar Agusti; Per Bakke; Konstantinos Bartziokas; Bianca Beghe; Andras Bikov; Thomas Bradbury; Guy Brusselle; Cordula Cadus; Courtney Coleman; Marco Contoli; Alexandru Corlateanu; Olga Corlateanu; Gerard J. Criner; Balazs Csoma; Alexander Emelyanov; Rosa Faner; Gustavo Fernandez Romero; Zeineb Hammouda; Peter Horvath; Arturo Huerta Garcia; Michael Jacobs; Christine Jenkins; Guy Joos; Olga Kharevich; Konstantinos Kostikas; Elena Lapteva; Zsofia Lazar; Joerg D. Leuppi; Carol Liddle; John Linnell; Alejandra Lopez-Giraldo; Vanessa M. Mcdonald; Rune Nielsen; Alberto Papi; Isabel Saraiva; Galina Sergeeva; Agni Sioutkou; Pradeesh Sivapalan; Elizabeth Stovold; Hao Wang; Fuqiang Wen; Janelle Yorke; Paula R. Williamson; Jorgen Vestbo; Jens-Ulrik Jensen; Alexander G. Mathioudakis

doi:10.1183/13993003.congress-2025.PA356

Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials

Sachin Ananth^*
, Fekri Abroug
, Alvar Agusti
, Per Bakke
, Konstantinos Bartziokas
, Bianca Beghe
, Andras Bikov
, Thomas Bradbury
, Guy Brusselle
, Cordula Cadus
, Courtney Coleman
, Marco Contoli
, Alexandru Corlateanu
, Olga Corlateanu
, Gerard J. Criner
, Balazs Csoma
, Alexander Emelyanov
, Rosa Faner
, Gustavo Fernandez Romero
, Zeineb Hammouda

Peter Horvath, Arturo Huerta Garcia, Michael Jacobs, Christine Jenkins, Guy Joos, Olga Kharevich, Konstantinos Kostikas, Elena Lapteva, Zsofia Lazar, Joerg D. Leuppi, Carol Liddle, John Linnell, Alejandra Lopez-Giraldo, Vanessa M. Mcdonald, Rune Nielsen, Alberto Papi, Isabel Saraiva, Galina Sergeeva, Agni Sioutkou, Pradeesh Sivapalan, Elizabeth Stovold, Hao Wang, Fuqiang Wen, Janelle Yorke, Paula R. Williamson, Jorgen Vestbo, Jens-Ulrik Jensen, Alexander G. Mathioudakis

^*Corresponding author for this work

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Abstract

Introduction: Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments.

Aim: To assess which trial outcomes for exacerbation treatments are most important for patients with COPD.

Methods: Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials. Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year.

Results: Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male). 45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%). Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function (Figure 1). Dyspnoea was most prioritised in both groups.

Conclusions: COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea. The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.

Original language	English
Article number	PA356
Book series	European Respiratory Journal. Supplement
Volume	66
Issue number	Suppl. 69
ISSN	0904-1850
DOIs	https://doi.org/10.1183/13993003.congress-2025.PA356
Publication status	Published - 2025

Access to Document

10.1183/13993003.congress-2025.PA356

Library access?

Check availability at the Royal Danish Library

Cite this

Ananth, S., Abroug, F., Agusti, A., Bakke, P., Bartziokas, K., Beghe, B., Bikov, A., Bradbury, T., Brusselle, G., Cadus, C., Coleman, C., Contoli, M., Corlateanu, A., Corlateanu, O., Criner, G. J., Csoma, B., Emelyanov, A., Faner, R., Romero, G. F., ... Mathioudakis, A. G. (2025). Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials. European Respiratory Journal. Supplement, 66(Suppl. 69), Article PA356. https://doi.org/10.1183/13993003.congress-2025.PA356

Ananth, S, Abroug, F, Agusti, A, Bakke, P, Bartziokas, K, Beghe, B, Bikov, A, Bradbury, T, Brusselle, G, Cadus, C, Coleman, C, Contoli, M, Corlateanu, A, Corlateanu, O, Criner, GJ, Csoma, B, Emelyanov, A, Faner, R, Romero, GF, Hammouda, Z, Horvath, P, Garcia, AH, Jacobs, M, Jenkins, C, Joos, G, Kharevich, O, Kostikas, K, Lapteva, E, Lazar, Z, Leuppi, JD, Liddle, C, Linnell, J, Lopez-Giraldo, A, Mcdonald, VM, Nielsen, R, Papi, A, Saraiva, I, Sergeeva, G, Sioutkou, A, Sivapalan, P, Stovold, E, Wang, H, Wen, F, Yorke, J, Williamson, PR, Vestbo, J, Jensen, J-U & Mathioudakis, AG 2025, 'Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials', European Respiratory Journal. Supplement, vol. 66, no. Suppl. 69, PA356. https://doi.org/10.1183/13993003.congress-2025.PA356

@article{53babc81c0544aa48a128dc53cf5445e,

title = "Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials",

abstract = "Introduction: Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments. Aim: To assess which trial outcomes for exacerbation treatments are most important for patients with COPD. Methods: Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials. Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year. Results: Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2\% male). 45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0\%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0\%) and impact on social life (57.1\%). Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function (Figure 1). Dyspnoea was most prioritised in both groups. Conclusions: COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea. The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.",

author = "Sachin Ananth and Fekri Abroug and Alvar Agusti and Per Bakke and Konstantinos Bartziokas and Bianca Beghe and Andras Bikov and Thomas Bradbury and Guy Brusselle and Cordula Cadus and Courtney Coleman and Marco Contoli and Alexandru Corlateanu and Olga Corlateanu and Criner, \{Gerard J.\} and Balazs Csoma and Alexander Emelyanov and Rosa Faner and Romero, \{Gustavo Fernandez\} and Zeineb Hammouda and Peter Horvath and Garcia, \{Arturo Huerta\} and Michael Jacobs and Christine Jenkins and Guy Joos and Olga Kharevich and Konstantinos Kostikas and Elena Lapteva and Zsofia Lazar and Leuppi, \{Joerg D.\} and Carol Liddle and John Linnell and Alejandra Lopez-Giraldo and Mcdonald, \{Vanessa M.\} and Rune Nielsen and Alberto Papi and Isabel Saraiva and Galina Sergeeva and Agni Sioutkou and Pradeesh Sivapalan and Elizabeth Stovold and Hao Wang and Fuqiang Wen and Janelle Yorke and Williamson, \{Paula R.\} and Jorgen Vestbo and Jens-Ulrik Jensen and Mathioudakis, \{Alexander G.\}",

year = "2025",

doi = "10.1183/13993003.congress-2025.PA356",

language = "English",

volume = "66",

journal = "European Respiratory Journal. Supplement",

issn = "0904-1850",

publisher = "European Respiratory Society",

number = "Suppl. 69",

}

TY - ABST

T1 - Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials

AU - Ananth, Sachin

AU - Abroug, Fekri

AU - Agusti, Alvar

AU - Bakke, Per

AU - Bartziokas, Konstantinos

AU - Beghe, Bianca

AU - Bikov, Andras

AU - Bradbury, Thomas

AU - Brusselle, Guy

AU - Cadus, Cordula

AU - Coleman, Courtney

AU - Contoli, Marco

AU - Corlateanu, Alexandru

AU - Corlateanu, Olga

AU - Criner, Gerard J.

AU - Csoma, Balazs

AU - Emelyanov, Alexander

AU - Faner, Rosa

AU - Romero, Gustavo Fernandez

AU - Hammouda, Zeineb

AU - Horvath, Peter

AU - Garcia, Arturo Huerta

AU - Jacobs, Michael

AU - Jenkins, Christine

AU - Joos, Guy

AU - Kharevich, Olga

AU - Kostikas, Konstantinos

AU - Lapteva, Elena

AU - Lazar, Zsofia

AU - Leuppi, Joerg D.

AU - Liddle, Carol

AU - Linnell, John

AU - Lopez-Giraldo, Alejandra

AU - Mcdonald, Vanessa M.

AU - Nielsen, Rune

AU - Papi, Alberto

AU - Saraiva, Isabel

AU - Sergeeva, Galina

AU - Sioutkou, Agni

AU - Sivapalan, Pradeesh

AU - Stovold, Elizabeth

AU - Wang, Hao

AU - Wen, Fuqiang

AU - Yorke, Janelle

AU - Williamson, Paula R.

AU - Vestbo, Jorgen

AU - Jensen, Jens-Ulrik

AU - Mathioudakis, Alexander G.

PY - 2025

Y1 - 2025

N2 - Introduction: Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments. Aim: To assess which trial outcomes for exacerbation treatments are most important for patients with COPD. Methods: Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials. Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year. Results: Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male). 45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%). Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function (Figure 1). Dyspnoea was most prioritised in both groups. Conclusions: COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea. The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.

AB - Introduction: Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments. Aim: To assess which trial outcomes for exacerbation treatments are most important for patients with COPD. Methods: Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials. Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year. Results: Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male). 45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%). Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function (Figure 1). Dyspnoea was most prioritised in both groups. Conclusions: COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea. The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.

U2 - 10.1183/13993003.congress-2025.PA356

DO - 10.1183/13993003.congress-2025.PA356

M3 - Conference abstract in journal

SN - 0904-1850

VL - 66

JO - European Respiratory Journal. Supplement

JF - European Respiratory Journal. Supplement

IS - Suppl. 69

M1 - PA356

ER -